<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10674">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00635882</url>
  </required_header>
  <id_info>
    <org_study_id>P05122</org_study_id>
    <nct_id>NCT00635882</nct_id>
  </id_info>
  <brief_title>Asthma Study Comparing Anti-Inflammatory Effects of 3 Doses of Mometasone Furoate/Formoterol Fumarate and Medium Dose Mometasone Furoate (Study P05122 AM1)(COMPLETED)</brief_title>
  <official_title>A 2-Week Double-Blind, Placebo-Controlled, Parallel Group Study Comparing the Anti-Inflammatory Effects of Low, Medium, and High Dose Mometasone Furoate/Formoterol Fumarate MDI Formulation and Medium Dose Mometasone Furoate DPI and MDI Formulations in Adults and Adolescents With Persistent Allergic Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 2-week double-blind, placebo-controlled, parallel group study comparing the
      anti-inflammatory effects of low, medium, and high dose mometasone furoate/formoterol
      fumarate (MF/F) metered dose inhaler (MDI) formulation and medium dose mometasone furoate
      (MF) dry powder inhaler (DPI) and MDI formulations in adults and adolescents with persistent
      allergic asthma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 2-week double-blind, placebo-controlled, parallel group study comparing the
      anti-inflammatory effects of low, medium, and high dose mometasone furoate/formoterol
      fumarate MDI formulation and medium dose mometasone furoate (MF) DPI and MDI formulations in
      adults and adolescents with persistent allergic asthma. An open-label run in period is to be
      followed by a double-blind treatment period.

      A total of 90 subjects (15 per treatment) will be enrolled to ensure 12 subjects per
      treatment at the Day 14 evaluation, accounting for a 20% drop-out rate. A sample size of 12
      subjects per treatment is required to detect a treatment difference of 28% in percent change
      of eNO at Day 14, assuming a pooled standard deviation of 20% with a power of 90%. These
      estimates are based on examination of eNO levels in asthmatic vs healthy subjects in an
      article written by S.A. Kharitonov et. al, 2003.

      Subjects will be randomized to one of six treatment groups (MF/F MDI 100/10 mcg BID, MF/F
      MDI 200/10 mcg BID, MF/F MDI 400/10 mcg BID, MF DPI 200 mcg BID, MF MDI 200 mcg BID, or
      Placebo MDI BID) according to an Schering-Plough Research Institute (SPRI)
      computer-generated randomization schedule. Randomization will be performed in appropriately
      sized blocks using random numbers generated by statistical analysis software (SAS).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Mean Percent Change From Baseline to Day 14 in Exhaled Nitric Oxide (eNO) Parts Per Billion (Ppb)</measure>
    <time_frame>Baseline to Day 14</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change From Baseline to Day 7 in eNO Ppb</measure>
    <time_frame>Baseline to Day 7</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change From Baseline to Day 14 in Sputum Eosinophil Count (Percentage)</measure>
    <time_frame>Baseline to Day 14</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Day 15 of Mannitol Challenge</measure>
    <time_frame>Baseline to Day 15</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mannitol challenge (also referred to as PD15) is the provocative dose of mannitol required to produce a 15% reduction in the forced expiratory volume (in liters) in one second (FEV1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in AM Total Asthma Symptom Score at Days 2-15</measure>
    <time_frame>Baseline and Days 2-15</time_frame>
    <safety_issue>No</safety_issue>
    <description>Twice daily, participants rated the following asthma symptoms as experienced during the time period since the last evaluation: wheezing, difficulty breathing, and cough on a scale of 0 (none) to 3 (severe, very uncomfortable and interfered with most or all of normal daily activities/sleep). The total asthma symptom score ranged from 0 to 9. The results were recorded in the participant's diary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in PM Total Asthma Symptom Score at Days 1-15</measure>
    <time_frame>Baseline and Days 1-15</time_frame>
    <safety_issue>No</safety_issue>
    <description>Twice daily, participants rated the following asthma symptoms as experienced during the time period since the last evaluation: wheezing, difficulty breathing, and cough on a scale of 0 (none) to 3 (severe, very uncomfortable and interfered with most or all of normal daily activities/sleep). The total asthma symptom score ranged from 0 to 9. The results were recorded in the participant's diary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in AM Peak Expiratory Flow (PEF) at Days 2-15</measure>
    <time_frame>Baseline and Days 2-15</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in PM PEF at Days 1-15</measure>
    <time_frame>Baseline and Days 1-15</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Baseline Exhaled Nitric Oxide (eNO) Parts Per Billion (Ppb)</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">93</enrollment>
  <condition>Asthma</condition>
  <condition>Airway Inflammation</condition>
  <arm_group>
    <arm_group_label>MF/F MDI 100/10 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MF/F MDI 200/10 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MF/F MDI 400/10 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MF DPI 200 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MF MDI 200 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mometasone furoate/formoterol 100/10 mcg</intervention_name>
    <description>mometasone furoate/formoterol 100/10 mcg twice daily (BID) (two inhalations of MF/F 50/5 from a metered-dose inhaler) for 14 days</description>
    <arm_group_label>MF/F MDI 100/10 mcg</arm_group_label>
    <other_name>MF/F (SCH 418131)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mometasone furoate/formoterol 200/10 mcg</intervention_name>
    <description>mometasone furoate/formoterol 200/10 mcg twice daily (BID) (two inhalations of MF/F 100/5 from a metered-dose inhaler) for 14 days</description>
    <arm_group_label>MF/F MDI 200/10 mcg</arm_group_label>
    <other_name>MF/F 200/10 (SCH 418131)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mometasone furoate/formoterol 400/10 mcg</intervention_name>
    <description>mometasone furoate/formoterol 400/10 mcg twice daily (BID) (two inhalations of MF/F 200/5 mcg from a metered-dose inhaler) for 14 days</description>
    <arm_group_label>MF/F MDI 400/10 mcg</arm_group_label>
    <other_name>MF/F 400/10 (SCH 418131)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MF DPI 200 mcg</intervention_name>
    <description>MF DPI 200 mcg twice daily (BID) (one inhalation of MF DPI 200 mcg) for 14 days</description>
    <arm_group_label>MF DPI 200 mcg</arm_group_label>
    <other_name>mometasone furoate (SCH 32088)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MF MDI 200 mcg</intervention_name>
    <description>MF MDI 200 mcg twice daily (BID) (two inhalations of MF MDI 100 mcg) for 14 days</description>
    <arm_group_label>MF MDI 200 mcg</arm_group_label>
    <other_name>mometasone furoate (SCH 32088)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>MF/F MDI placebo twice daily (BID) (2 inhalations)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  To document asthma diagnosis, historical reversibility defined as an increase in
             absolute forced expiratory volume (in liters) in 1 second (FEV1) of &gt;= 12% and &gt;= 200
             mL must have been performed within 12 months of Screening. For subjects without
             historical reversibility, one of the following methods can be used at the Screening
             Visit or at any time before the Baseline Visit:

               -  Demonstration of an increase in absolute FEV1 of at least 12% and a volume
                  increase of at least 200 mL within 15-20 minutes after administration of 4
                  inhalations of albuterol/salbutamol (total dose 360 to 400 mcg) or of nebulized
                  short-acting beta agonist (SABA) (2.5 mg), if confirmed as standard office
                  practice, OR

               -  Demonstration of a peak expiratory flow (PEF) variability of more than 20%
                  expressed as a percentage of the mean highest and lowest morning
                  prebronchodilator PEF over at least 1 week, OR

               -  Demonstration of a diurnal variation PEF of more than 20% based on the
                  difference between the prebronchodilator (before taking albuterol/salbutamol)
                  morning value and the postbronchodilator value (after taking
                  albuterol/salbutamol) from the evening before, expressed as a percentage of the
                  mean daily PEF value on any day during the open-label Run-in Period. {The
                  calculation formula: Diurnal PEF Variation = Absolute [(highest of 3 readings,
                  PM Post-bronchodilator (BD) PEF from prior evening) - (highest of 3 readings, AM
                  Pre-BD from morning value)]/[(highest PM Post-BD + highest AM Pre-BD)/2] * 100}

          -  At Screening and Baseline Visits, a subject must have persistent allergic asthma with
             an FEV1 &gt;65% predicted.

          -  A subject must be allergic to at least one common allergen (grasses, trees, weeds,
             house dust mites, molds, dog and cat) as demonstrated by clinical symptoms when
             exposed to the allergen(s), and by skin prick testing or a radioallergosorbent (RAST)
             class &gt;1 (excluding modified RAST procedure [mRAST]) within 2 years of inclusion in
             the study.

          -  If, based upon the medical judgment of the investigator, there is no inherent harm in
             changing the subject's current asthma therapy, the subject and/or parent/guardian)
             must agree to discontinue prescribed inhaled corticosteroid (ICS), anticholinergics,
             leukotriene receptor inhibitors, and long-acting beta-2 agonists at the Screening
             Visit as per required washouts, and be transferred to treatment with SABA for relief
             for 2 weeks before the Baseline/Randomization Visit.

          -  Clinical laboratory tests (complete blood count, blood chemistries, and urinalysis)
             conducted at the Screening Visit must be within normal limits or clinically
             acceptable to the investigator.

          -  An electrocardiogram (ECG) performed at the Screening Visit or within 30 days prior
             to Screening Visit must be clinically acceptable to the investigator and have a QTc
             interval &lt;440 milliseconds for males and &lt;450 msec for females.

          -  At Screening or any time prior to Baseline, a subject must have an eNO level of &gt;30
             parts per billion (ppb) at a flow rate of 50 mL/second.

          -  At Screening or any time before Baseline, a subject must have a sputum eosinophil
             count &gt;3% of total cell count.

          -  Willingness to give written informed consent and ability to adhere to dose and visit
             schedules. A subject 12 to 17 years of age must also provide written assent.

          -  A nonpregnant female subject of childbearing potential (with a negative serum
             pregnancy test at Screening) must use a medically acceptable, adequate form of birth
             control. If not currently sexually active she must agree to use a double-barrier
             method if she becomes sexually active during the study.

        Exclusion Criteria:

          -  Use of systemic glucocorticosteroids within 3 months before Screening.

          -  Upper or lower respiratory tract infection within 4 weeks before Screening.

          -  Decrease in absolute FEV1 &gt;20% between Screening and Baseline Visits.

          -  Requirement for &gt; 8 inhalations per day of SABA MDI, or 2 or more nebulized
             treatments of 2.5 mg SABA, on any 2 consecutive days between the Screening and
             Baseline Visits.

          -  A decrease in AM or PM PEF below the Run-in Period stability limit on any 2
             consecutive days before Baseline. At Visit 1, the Run-in Period stability limit for
             PEF will be established based on the subject's personal best. If the subject does not
             have a historical personal best, the historical PEF measurement will be the PEF
             predicted based on the subject's sex, age, and height. PEF value to be multiplied by
             0.70 to determine stability limit.

          -  A clinical asthma exacerbation defined as a clinical deterioration of asthma that
             results in emergency treatment, hospitalization for asthma, or treatment with
             additional, excluded asthma medication (including oral or other systemic
             corticosteroids but allowing SABA), as per investigator, between Screening and
             Baseline Visits.

          -  Inability to induce sputum after 1 or 2 trys.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Sweden</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>September 2015</verification_date>
  <lastchanged_date>September 18, 2015</lastchanged_date>
  <firstreceived_date>January 21, 2008</firstreceived_date>
  <firstreceived_results_date>October 22, 2010</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mometasone</keyword>
  <keyword>formoterol</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
    <mesh_term>Formoterol</mesh_term>
    <mesh_term>Mometasone furoate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>MF/F MDI 100/10 mcg</title>
          <description>Mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) 100/10 mcg twice daily (BID) for 14 days</description>
        </group>
        <group group_id="P2">
          <title>MF/F MDI 200/10 mcg</title>
          <description>MF/F MDI 200/10 mcg BID for 14 days</description>
        </group>
        <group group_id="P3">
          <title>MF/F MDI 400/10 mcg</title>
          <description>MF/F MDI 400/10 mcg BID for 14 days</description>
        </group>
        <group group_id="P4">
          <title>MF DPI 200 mcg</title>
          <description>Mometasone furoate (MF) dry powder inhaler (DPI) 200 mcg BID for 14 days</description>
        </group>
        <group group_id="P5">
          <title>MF MDI 200 mcg</title>
          <description>MF MDI 200 mcg BID for 14 days</description>
        </group>
        <group group_id="P6">
          <title>Placebo</title>
          <description>Placebo MDI BID for 14 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="16"/>
                <participants group_id="P6" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="16"/>
                <participants group_id="P6" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MF/F MDI 100/10 mcg</title>
          <description>Mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) 100/10 mcg twice daily (BID) for 14 days</description>
        </group>
        <group group_id="B2">
          <title>MF/F MDI 200/10 mcg</title>
          <description>MF/F MDI 200/10 mcg BID for 14 days</description>
        </group>
        <group group_id="B3">
          <title>MF/F MDI 400/10 mcg</title>
          <description>MF/F MDI 400/10 mcg BID for 14 days</description>
        </group>
        <group group_id="B4">
          <title>MF DPI 200 mcg</title>
          <description>Mometasone furoate (MF) dry powder inhaler (DPI) 200 mcg BID for 14 days</description>
        </group>
        <group group_id="B5">
          <title>MF MDI 200 mcg</title>
          <description>MF MDI 200 mcg BID for 14 days</description>
        </group>
        <group group_id="B6">
          <title>Placebo</title>
          <description>Placebo MDI BID for 14 days</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
                <measurement group_id="B2" value="17"/>
                <measurement group_id="B3" value="12"/>
                <measurement group_id="B4" value="15"/>
                <measurement group_id="B5" value="16"/>
                <measurement group_id="B6" value="13"/>
                <measurement group_id="B7" value="93"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>18 to &lt;65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
                <measurement group_id="B2" value="14"/>
                <measurement group_id="B3" value="11"/>
                <measurement group_id="B4" value="15"/>
                <measurement group_id="B5" value="16"/>
                <measurement group_id="B6" value="11"/>
                <measurement group_id="B7" value="87"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt; or = to 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="1"/>
                <measurement group_id="B4" value="0"/>
                <measurement group_id="B5" value="0"/>
                <measurement group_id="B6" value="2"/>
                <measurement group_id="B7" value="6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="13"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="4"/>
                <measurement group_id="B4" value="6"/>
                <measurement group_id="B5" value="6"/>
                <measurement group_id="B6" value="8"/>
                <measurement group_id="B7" value="47"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
                <measurement group_id="B2" value="7"/>
                <measurement group_id="B3" value="8"/>
                <measurement group_id="B4" value="9"/>
                <measurement group_id="B5" value="10"/>
                <measurement group_id="B6" value="5"/>
                <measurement group_id="B7" value="46"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Percent Change From Baseline to Day 14 in Exhaled Nitric Oxide (eNO) Parts Per Billion (Ppb)</title>
        <time_frame>Baseline to Day 14</time_frame>
        <safety_issue>No</safety_issue>
        <population>All Randomized Participants</population>
        <group_list>
          <group group_id="O1">
            <title>MF/F MDI 100/10 mcg</title>
            <description>Mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) 100/10 mcg twice daily (BID) for 14 days</description>
          </group>
          <group group_id="O2">
            <title>MF/F MDI 200/10 mcg</title>
            <description>MF/F MDI 200/10 mcg BID for 14 days</description>
          </group>
          <group group_id="O3">
            <title>MF/F MDI 400/10 mcg</title>
            <description>MF/F MDI 400/10 mcg BID for 14 days</description>
          </group>
          <group group_id="O4">
            <title>MF DPI 200 mcg</title>
            <description>Mometasone furoate (MF) dry powder inhaler (DPI) 200 mcg BID for 14 days</description>
          </group>
          <group group_id="O5">
            <title>MF MDI 200 mcg</title>
            <description>MF MDI 200 mcg BID for 14 days</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo MDI BID for 14 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="16"/>
                  <measurement group_id="O3" value="12"/>
                  <measurement group_id="O4" value="14"/>
                  <measurement group_id="O5" value="15"/>
                  <measurement group_id="O6" value="13"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Percent Change From Baseline to Day 14 in Exhaled Nitric Oxide (eNO) Parts Per Billion (Ppb)</title>
            <units>percentage of eNO</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-35.3" spread="40.3"/>
                  <measurement group_id="O2" value="-45.4" spread="40.3"/>
                  <measurement group_id="O3" value="-61.4" spread="40.3"/>
                  <measurement group_id="O4" value="-51.3" spread="40.3"/>
                  <measurement group_id="O5" value="-46.1" spread="40.3"/>
                  <measurement group_id="O6" value="0.1" spread="40.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Analysis of covariance (ANCOVA) model with treatment and baseline eNO as a covariate was used.
Standard deviation is a Pooled Standard deviation from ANCOVA Model with treatment effect and baseline eNO as a covariate.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>ANCOVA model with treatment and baseline eNO as a covariate was used.
Standard deviation is a Pooled Standard deviation from ANCOVA Model with treatment effect and baseline eNO as a covariate.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.003</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>ANCOVA model with treatment and baseline eNO as a covariate was used.
Standard deviation is a Pooled Standard deviation from ANCOVA Model with treatment effect and baseline eNO as a covariate.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.018</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Change From Baseline to Day 7 in eNO Ppb</title>
        <time_frame>Baseline to Day 7</time_frame>
        <safety_issue>No</safety_issue>
        <population>All Randomized Participants</population>
        <group_list>
          <group group_id="O1">
            <title>MF/F MDI 100/10 mcg</title>
            <description>Mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) 100/10 mcg twice daily (BID) for 14 days</description>
          </group>
          <group group_id="O2">
            <title>MF/F MDI 200/10 mcg</title>
            <description>MF/F MDI 200/10 mcg BID for 14 days</description>
          </group>
          <group group_id="O3">
            <title>MF/F MDI 400/10 mcg</title>
            <description>MF/F MDI 400/10 mcg BID for 14 days</description>
          </group>
          <group group_id="O4">
            <title>MF DPI 200 mcg</title>
            <description>Mometasone furoate (MF) dry powder inhaler (DPI) 200 mcg BID for 14 days</description>
          </group>
          <group group_id="O5">
            <title>MF MDI 200 mcg</title>
            <description>MF MDI 200 mcg BID for 14 days</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo MDI BID for 14 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="16"/>
                  <measurement group_id="O3" value="12"/>
                  <measurement group_id="O4" value="14"/>
                  <measurement group_id="O5" value="15"/>
                  <measurement group_id="O6" value="13"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Percent Change From Baseline to Day 7 in eNO Ppb</title>
            <units>percentage of eNO</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-37.9" spread="36.3"/>
                  <measurement group_id="O2" value="-39.7" spread="36.3"/>
                  <measurement group_id="O3" value="-45.6" spread="36.3"/>
                  <measurement group_id="O4" value="-46.0" spread="36.3"/>
                  <measurement group_id="O5" value="-37.2" spread="36.3"/>
                  <measurement group_id="O6" value="4.8" spread="36.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>ANCOVA model with treatment and baseline eNO as a covariate was used.
Standard deviation is a Pooled Standard deviation from ANCOVA Model with treatment effect and baseline eNO as a covariate.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>ANCOVA model with treatment and baseline eNO as a covariate was used.
Standard deviation is a Pooled Standard deviation from ANCOVA Model with treatment effect and baseline eNO as a covariate.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.002</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>ANCOVA model with treatment and baseline eNO as a covariate was used.
Standard deviation is a Pooled Standard deviation from ANCOVA Model with treatment effect and baseline eNO as a covariate.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.002</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Change From Baseline to Day 14 in Sputum Eosinophil Count (Percentage)</title>
        <time_frame>Baseline to Day 14</time_frame>
        <safety_issue>No</safety_issue>
        <population>All randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>MF/F MDI 100/10 mcg</title>
            <description>Mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) 100/10 mcg twice daily (BID) for 14 days</description>
          </group>
          <group group_id="O2">
            <title>MF/F MDI 200/10 mcg</title>
            <description>MF/F MDI 200/10 mcg BID for 14 days</description>
          </group>
          <group group_id="O3">
            <title>MF/F MDI 400/10 mcg</title>
            <description>MF/F MDI 400/10 mcg BID for 14 days</description>
          </group>
          <group group_id="O4">
            <title>MF DPI 200 mcg</title>
            <description>Mometasone furoate (MF) dry powder inhaler (DPI) 200 mcg BID for 14 days</description>
          </group>
          <group group_id="O5">
            <title>MF MDI 200 mcg</title>
            <description>MF MDI 200 mcg BID for 14 days</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo MDI BID for 14 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="13"/>
                  <measurement group_id="O3" value="7"/>
                  <measurement group_id="O4" value="12"/>
                  <measurement group_id="O5" value="11"/>
                  <measurement group_id="O6" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Percent Change From Baseline to Day 14 in Sputum Eosinophil Count (Percentage)</title>
            <units>percentage of Sputum Eosinophil Count</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="21.1" spread="127.6"/>
                  <measurement group_id="O2" value="-35.5" spread="127.6"/>
                  <measurement group_id="O3" value="-75.4" spread="127.6"/>
                  <measurement group_id="O4" value="-55.3" spread="127.6"/>
                  <measurement group_id="O5" value="-33.7" spread="127.6"/>
                  <measurement group_id="O6" value="71.7" spread="127.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>ANCOVA model with treatment and baseline eosinophils as a covariate was used.
Standard deviation is a Pooled Standard deviation from ANCOVA Model with treatment effect and baseline EOS as a covariate.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.024</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>ANCOVA model with treatment and baseline eosinophils as a covariate was used.
Standard deviation is a Pooled Standard deviation from ANCOVA Model with treatment effect and baseline EOS as a covariate.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.051</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>ANCOVA model with treatment and baseline eosinophils as a covariate was used.
Standard deviation is a Pooled Standard deviation from ANCOVA Model with treatment effect and baseline EOS as a covariate.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.336</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Day 15 of Mannitol Challenge</title>
        <description>Mannitol challenge (also referred to as PD15) is the provocative dose of mannitol required to produce a 15% reduction in the forced expiratory volume (in liters) in one second (FEV1).</description>
        <time_frame>Baseline to Day 15</time_frame>
        <safety_issue>No</safety_issue>
        <population>All randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>MF/F MDI 100/10 mcg</title>
            <description>Mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) 100/10 mcg twice daily (BID) for 14 days</description>
          </group>
          <group group_id="O2">
            <title>MF/F MDI 200/10 mcg</title>
            <description>MF/F MDI 200/10 mcg BID for 14 days</description>
          </group>
          <group group_id="O3">
            <title>MF/F MDI 400/10 mcg</title>
            <description>MF/F MDI 400/10 mcg BID for 14 days</description>
          </group>
          <group group_id="O4">
            <title>MF DPI 200 mcg</title>
            <description>Mometasone furoate (MF) dry powder inhaler (DPI) 200 mcg BID for 14 days</description>
          </group>
          <group group_id="O5">
            <title>MF MDI 200 mcg</title>
            <description>MF MDI 200 mcg BID for 14 days</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo MDI BID for 14 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="9"/>
                  <measurement group_id="O3" value="6"/>
                  <measurement group_id="O4" value="8"/>
                  <measurement group_id="O5" value="9"/>
                  <measurement group_id="O6" value="9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Change From Baseline to Day 15 of Mannitol Challenge</title>
            <description>Mannitol challenge (also referred to as PD15) is the provocative dose of mannitol required to produce a 15% reduction in the forced expiratory volume (in liters) in one second (FEV1).</description>
            <units>milligrams</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="102.2" spread="106.7"/>
                  <measurement group_id="O2" value="48.6" spread="106.7"/>
                  <measurement group_id="O3" value="67.9" spread="106.7"/>
                  <measurement group_id="O4" value="137.6" spread="106.7"/>
                  <measurement group_id="O5" value="126.0" spread="106.7"/>
                  <measurement group_id="O6" value="159.4" spread="106.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Mean Change from Baseline to Day 15</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="176.6" spread="264"/>
                  <measurement group_id="O2" value="153.8" spread="264"/>
                  <measurement group_id="O3" value="162.9" spread="264"/>
                  <measurement group_id="O4" value="159.4" spread="264"/>
                  <measurement group_id="O5" value="146.2" spread="264"/>
                  <measurement group_id="O6" value="-63.7" spread="264"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>ANCOVA model with treatment and baseline PD15 as a covariate was used.
Standard deviation is a Pooled Standard deviation from ANCOVA Model with treatment effect and baseline PD15 as a covariate.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.120</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis applies to Mean Change from Baseline to Day 15.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>ANCOVA model with treatment and baseline PD15 as a covariate was used.
Standard deviation is a Pooled Standard deviation from ANCOVA Model with treatment effect and baseline PD15 as a covariate.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.103</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis applies to Mean Change from Baseline to Day 15.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>ANCOVA model with treatment and baseline PD15 as a covariate was used.
Standard deviation is a Pooled Standard deviation from ANCOVA Model with treatment effect and baseline PD15 as a covariate.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.048</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis applies to Mean Change from Baseline to Day 15.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in AM Total Asthma Symptom Score at Days 2-15</title>
        <description>Twice daily, participants rated the following asthma symptoms as experienced during the time period since the last evaluation: wheezing, difficulty breathing, and cough on a scale of 0 (none) to 3 (severe, very uncomfortable and interfered with most or all of normal daily activities/sleep). The total asthma symptom score ranged from 0 to 9. The results were recorded in the participant's diary.</description>
        <time_frame>Baseline and Days 2-15</time_frame>
        <safety_issue>No</safety_issue>
        <population>All randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>MF/F MDI 100/10 mcg</title>
            <description>Mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) 100/10 mcg twice daily (BID) for 14 days</description>
          </group>
          <group group_id="O2">
            <title>MF/F MDI 200/10 mcg</title>
            <description>MF/F MDI 200/10 mcg BID for 14 days</description>
          </group>
          <group group_id="O3">
            <title>MF/F MDI 400/10 mcg</title>
            <description>MF/F MDI 400/10 mcg BID for 14 days</description>
          </group>
          <group group_id="O4">
            <title>MF DPI 200 mcg</title>
            <description>Mometasone furoate (MF) dry powder inhaler (DPI) 200 mcg BID for 14 days</description>
          </group>
          <group group_id="O5">
            <title>MF MDI 200 mcg</title>
            <description>MF MDI 200 mcg BID for 14 days</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo MDI BID for 14 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="17"/>
                  <measurement group_id="O3" value="12"/>
                  <measurement group_id="O4" value="15"/>
                  <measurement group_id="O5" value="16"/>
                  <measurement group_id="O6" value="13"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in AM Total Asthma Symptom Score at Days 2-15</title>
            <description>Twice daily, participants rated the following asthma symptoms as experienced during the time period since the last evaluation: wheezing, difficulty breathing, and cough on a scale of 0 (none) to 3 (severe, very uncomfortable and interfered with most or all of normal daily activities/sleep). The total asthma symptom score ranged from 0 to 9. The results were recorded in the participant's diary.</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.6" spread="1.66"/>
                  <measurement group_id="O2" value="1.2" spread="1.66"/>
                  <measurement group_id="O3" value="2.2" spread="1.66"/>
                  <measurement group_id="O4" value="1.5" spread="1.66"/>
                  <measurement group_id="O5" value="1.1" spread="1.66"/>
                  <measurement group_id="O6" value="1.4" spread="1.66"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Mean Change from Baseline to Days 2-15</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.7" spread="1.28"/>
                  <measurement group_id="O2" value="-0.7" spread="1.28"/>
                  <measurement group_id="O3" value="-1.5" spread="1.28"/>
                  <measurement group_id="O4" value="-1.2" spread="1.28"/>
                  <measurement group_id="O5" value="-0.5" spread="1.28"/>
                  <measurement group_id="O6" value="-0.2" spread="1.28"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>One-way analysis of variance (ANOVA) model with treatment effect was used.
Standard deviation is a Pooled Standard deviation from the one-way ANOVA model with treatment effect.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.018</p_value>
            <method>ANOVA</method>
            <method_desc>Analysis applies to Mean Change from Baseline to Days 2-15.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>One-way ANOVA model with treatment effect was used.
Standard deviation is a Pooled Standard deviation from the one-way ANOVA model with treatment effect.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.261</p_value>
            <method>ANOVA</method>
            <method_desc>Analysis applies to Mean Change from Baseline to Days 2-15.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>One-way ANOVA model with treatment effect was used.
Standard deviation is a Pooled Standard deviation from the one-way ANOVA model with treatment effect.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.334</p_value>
            <method>ANOVA</method>
            <method_desc>Analysis applies to Mean Change from Baseline to Days 2-15.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in PM Total Asthma Symptom Score at Days 1-15</title>
        <description>Twice daily, participants rated the following asthma symptoms as experienced during the time period since the last evaluation: wheezing, difficulty breathing, and cough on a scale of 0 (none) to 3 (severe, very uncomfortable and interfered with most or all of normal daily activities/sleep). The total asthma symptom score ranged from 0 to 9. The results were recorded in the participant's diary.</description>
        <time_frame>Baseline and Days 1-15</time_frame>
        <safety_issue>No</safety_issue>
        <population>All randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>MF/F MDI 100/10 mcg</title>
            <description>Mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) 100/10 mcg twice daily (BID) for 14 days</description>
          </group>
          <group group_id="O2">
            <title>MF/F MDI 200/10 mcg</title>
            <description>MF/F MDI 200/10 mcg BID for 14 days</description>
          </group>
          <group group_id="O3">
            <title>MF/F MDI 400/10 mcg</title>
            <description>MF/F MDI 400/10 mcg BID for 14 days</description>
          </group>
          <group group_id="O4">
            <title>MF DPI 200 mcg</title>
            <description>Mometasone furoate (MF) dry powder inhaler (DPI) 200 mcg BID for 14 days</description>
          </group>
          <group group_id="O5">
            <title>MF MDI 200 mcg</title>
            <description>MF MDI 200 mcg BID for 14 days</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo MDI BID for 14 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="17"/>
                  <measurement group_id="O3" value="12"/>
                  <measurement group_id="O4" value="15"/>
                  <measurement group_id="O5" value="15"/>
                  <measurement group_id="O6" value="13"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in PM Total Asthma Symptom Score at Days 1-15</title>
            <description>Twice daily, participants rated the following asthma symptoms as experienced during the time period since the last evaluation: wheezing, difficulty breathing, and cough on a scale of 0 (none) to 3 (severe, very uncomfortable and interfered with most or all of normal daily activities/sleep). The total asthma symptom score ranged from 0 to 9. The results were recorded in the participant's diary.</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.7" spread="1.62"/>
                  <measurement group_id="O2" value="1.1" spread="1.62"/>
                  <measurement group_id="O3" value="2.1" spread="1.62"/>
                  <measurement group_id="O4" value="1.6" spread="1.62"/>
                  <measurement group_id="O5" value="1.6" spread="1.62"/>
                  <measurement group_id="O6" value="1.7" spread="1.62"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Mean Change from Baseline to Days 1-15</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.4" spread="1.24"/>
                  <measurement group_id="O2" value="-0.6" spread="1.24"/>
                  <measurement group_id="O3" value="-1.4" spread="1.24"/>
                  <measurement group_id="O4" value="-1.1" spread="1.24"/>
                  <measurement group_id="O5" value="-0.7" spread="1.24"/>
                  <measurement group_id="O6" value="-0.3" spread="1.24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>One-way ANOVA model with treatment effect was used.
Standard deviation is a Pooled Standard deviation from the one-way ANOVA model with treatment effect.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.037</p_value>
            <method>ANOVA</method>
            <method_desc>Analysis applies to Mean Change from Baseline to Days 1-15.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>One-way ANOVA model with treatment effect was used.
Standard deviation is a Pooled Standard deviation from the one-way ANOVA model with treatment effect.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.643</p_value>
            <method>ANOVA</method>
            <method_desc>Analysis applies to Mean Change from Baseline to Days 1-15.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>One-way ANOVA model with treatment effect was used.
Standard deviation is a Pooled Standard deviation from the one-way ANOVA model with treatment effect.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.963</p_value>
            <method>ANOVA</method>
            <method_desc>Analysis applies to Mean Change from Baseline to Days 1-15.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in AM Peak Expiratory Flow (PEF) at Days 2-15</title>
        <time_frame>Baseline and Days 2-15</time_frame>
        <safety_issue>No</safety_issue>
        <population>All randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>MF/F MDI 100/10 mcg</title>
            <description>Mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) 100/10 mcg twice daily (BID) for 14 days</description>
          </group>
          <group group_id="O2">
            <title>MF/F MDI 200/10 mcg</title>
            <description>MF/F MDI 200/10 mcg BID for 14 days</description>
          </group>
          <group group_id="O3">
            <title>MF/F MDI 400/10 mcg</title>
            <description>MF/F MDI 400/10 mcg BID for 14 days</description>
          </group>
          <group group_id="O4">
            <title>MF DPI 200 mcg</title>
            <description>Mometasone furoate (MF) dry powder inhaler (DPI) 200 mcg BID for 14 days</description>
          </group>
          <group group_id="O5">
            <title>MF MDI 200 mcg</title>
            <description>MF MDI 200 mcg BID for 14 days</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo MDI BID for 14 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="17"/>
                  <measurement group_id="O3" value="12"/>
                  <measurement group_id="O4" value="15"/>
                  <measurement group_id="O5" value="16"/>
                  <measurement group_id="O6" value="13"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in AM Peak Expiratory Flow (PEF) at Days 2-15</title>
            <units>liters/minute</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="452.6" spread="112.1"/>
                  <measurement group_id="O2" value="421.2" spread="112.1"/>
                  <measurement group_id="O3" value="468.7" spread="112.1"/>
                  <measurement group_id="O4" value="466.3" spread="112.1"/>
                  <measurement group_id="O5" value="473.3" spread="112.1"/>
                  <measurement group_id="O6" value="413.2" spread="112.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Mean Change from Baseline to Days 2-15</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="48.1" spread="47.0"/>
                  <measurement group_id="O2" value="46.9" spread="47.0"/>
                  <measurement group_id="O3" value="69.8" spread="47.0"/>
                  <measurement group_id="O4" value="30.3" spread="47.0"/>
                  <measurement group_id="O5" value="30.8" spread="47.0"/>
                  <measurement group_id="O6" value="-9.0" spread="47.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>One-way ANOVA model with treatment effect was used.
Standard deviation is a Pooled Standard deviation from the one-way ANOVA model with treatment effect.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>Analysis applies to Mean Change from Baseline to Days 2-15.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>One-way ANOVA model with treatment effect was used.
Standard deviation is a Pooled Standard deviation from the one-way ANOVA model with treatment effect.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.002</p_value>
            <method>ANOVA</method>
            <method_desc>Analysis applies to Mean Change from Baseline to Days 2-15.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>One-way ANOVA model with treatment effect was used.
Standard deviation is a Pooled Standard deviation from the one-way ANOVA model with treatment effect.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>Analysis applies to Mean Change from Baseline to Days 2-15.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in PM PEF at Days 1-15</title>
        <time_frame>Baseline and Days 1-15</time_frame>
        <safety_issue>No</safety_issue>
        <population>All randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>MF/F MDI 100/10 mcg</title>
            <description>Mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) 100/10 mcg twice daily (BID) for 14 days</description>
          </group>
          <group group_id="O2">
            <title>MF/F MDI 200/10 mcg</title>
            <description>MF/F MDI 200/10 mcg BID for 14 days</description>
          </group>
          <group group_id="O3">
            <title>MF/F MDI 400/10 mcg</title>
            <description>MF/F MDI 400/10 mcg BID for 14 days</description>
          </group>
          <group group_id="O4">
            <title>MF DPI 200 mcg</title>
            <description>Mometasone furoate (MF) dry powder inhaler (DPI) 200 mcg BID for 14 days</description>
          </group>
          <group group_id="O5">
            <title>MF MDI 200 mcg</title>
            <description>MF MDI 200 mcg BID for 14 days</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo MDI BID for 14 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="17"/>
                  <measurement group_id="O3" value="12"/>
                  <measurement group_id="O4" value="15"/>
                  <measurement group_id="O5" value="15"/>
                  <measurement group_id="O6" value="13"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in PM PEF at Days 1-15</title>
            <units>liters/minute</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="462.0" spread="114.6"/>
                  <measurement group_id="O2" value="437.2" spread="114.6"/>
                  <measurement group_id="O3" value="486.7" spread="114.6"/>
                  <measurement group_id="O4" value="484.4" spread="114.6"/>
                  <measurement group_id="O5" value="472.5" spread="114.6"/>
                  <measurement group_id="O6" value="422.7" spread="114.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Mean Change from Baseline to Days 1-15</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="47.7" spread="42.3"/>
                  <measurement group_id="O2" value="34.5" spread="42.3"/>
                  <measurement group_id="O3" value="66.8" spread="42.3"/>
                  <measurement group_id="O4" value="20.2" spread="42.3"/>
                  <measurement group_id="O5" value="28.3" spread="42.3"/>
                  <measurement group_id="O6" value="4.5" spread="42.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>One-way ANOVA model with treatment effect was used.
Standard deviation is a Pooled Standard deviation from the one-way ANOVA model with treatment effect.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>Analysis applies to Mean Change from Baseline to Days 1-15.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>One-way ANOVA model with treatment effect was used.
Standard deviation is a Pooled Standard deviation from the one-way ANOVA model with treatment effect.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.057</p_value>
            <method>ANOVA</method>
            <method_desc>Analysis applies to Mean Change from Baseline to Days 1-15.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>One-way ANOVA model with treatment effect was used.
Standard deviation is a Pooled Standard deviation from the one-way ANOVA model with treatment effect.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.005</p_value>
            <method>ANOVA</method>
            <method_desc>Analysis applies to Mean Change from Baseline to Days 1-15.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Baseline Exhaled Nitric Oxide (eNO) Parts Per Billion (Ppb)</title>
        <time_frame>Baseline</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>MF/F MDI 100/10 mcg</title>
            <description>Mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) 100/10 mcg twice daily (BID) for 14 days</description>
          </group>
          <group group_id="O2">
            <title>MF/F MDI 200/10 mcg</title>
            <description>MF/F MDI 200/10 mcg BID for 14 days</description>
          </group>
          <group group_id="O3">
            <title>MF/F MDI 400/10 mcg</title>
            <description>MF/F MDI 400/10 mcg BID for 14 days</description>
          </group>
          <group group_id="O4">
            <title>MF DPI 200 mcg</title>
            <description>Mometasone furoate (MF) dry powder inhaler (DPI) 200 mcg BID for 14 days</description>
          </group>
          <group group_id="O5">
            <title>MF MDI 200 mcg</title>
            <description>MF MDI 200 mcg BID for 14 days</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo MDI BID for 14 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="16"/>
                  <measurement group_id="O3" value="12"/>
                  <measurement group_id="O4" value="14"/>
                  <measurement group_id="O5" value="15"/>
                  <measurement group_id="O6" value="13"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Baseline Exhaled Nitric Oxide (eNO) Parts Per Billion (Ppb)</title>
            <units>ppb</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="54.8" spread="40.8"/>
                  <measurement group_id="O2" value="70.0" spread="40.8"/>
                  <measurement group_id="O3" value="77.1" spread="40.8"/>
                  <measurement group_id="O4" value="102.6" spread="40.8"/>
                  <measurement group_id="O5" value="66.2" spread="40.8"/>
                  <measurement group_id="O6" value="79.6" spread="40.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>MF/F MDI 100/10 MCG BID</title>
        </group>
        <group group_id="E2">
          <title>MF/F MDI 200/10 MCG BID</title>
        </group>
        <group group_id="E3">
          <title>MF/F MDI 400/10 MCG BID</title>
        </group>
        <group group_id="E4">
          <title>MF DPI 200 MCG BID</title>
        </group>
        <group group_id="E5">
          <title>MF MDI 200 MCG BID</title>
        </group>
        <group group_id="E6">
          <title>PLACEBO</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>EAR DISCOMFORT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>ORAL CANDIDIASIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>SPINAL CORD INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>SUNBURN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>DRY THROAT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>DYSPHONIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>NASAL CONGESTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>RHINITIS ALLERGIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>THROAT IRRITATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>PAIN OF SKIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The investigator agrees not to publish/present any interim results without prior
sponsor written consent. The investigator agrees to provide to the sponsor, 45 days prior to submission, review copies for publication that report any study results. The sponsor has the right to review and comment. If the parties disagree, investigator agrees to meet with the sponsor, prior to submission for publication, to discuss and resolve any such issues/disagreement.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
